Olaris secures undisclosed investment from Bruker Corporation to enhance its metabolomics platform for improved disease diagnostics. The funding will support commercialization efforts.

May 19, 2025•3 months ago

FraminghamBiotechnologyHealth Care

Investors

Bruker Corporation

Description

Olaris, a Framingham, MA-based metabolomics and precision medicine company, received an investment from Bruker Corporation. The amount of the deal was not disclosed. The company intends to use the funds to support the continued development and commercialization of its proprietary metabolomics platform. This platform leverages machine learning and metabolite biomarker discovery for improved disease diagnostics.

Company Information

Company

Olaris

Location

Framingham, Massachusetts, United States

About

Olaris is a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARIS™ diagnostics products, which aim to optimize treatments and outcomes for individual patients. Metabolite diagnostics empower therapeutic selection, treatment effectiveness monitoring, disease diagnosis, and target identification across indications and therapeutics areas, including oncology, solid-organ transplant, and neurodegeneration. Our mission is to remove the guesswork from medicine.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers